Oncology

Stemline gives in-licenses global rights to SL-1001 Stemline Therapeutics, Inc. is a biopharmaceutical company focused on development and commercialization of novel oncology therapeutics, has licensed worldwide rights to a preclinical molecule RET (rearranged during transfection) kinase inhibitor. The RET kinase genetic mutations are found in a wide range of cancers and are prime targets in most of them. The Compound- SL-1001, designed by the scientists at Cancer Research UK Manchester Institute at the University of Manchester (United Kingdom), has shown its potential in targeting the RET molecule showing its anti-cancer nature. HIV injectable treatment a huge ...